Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update

Dominari Holdings Inc. (NASDAQ:DOMHGet Free Report) saw a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 3,100 shares, a growth of 10.7% from the February 14th total of 2,800 shares. Based on an average daily volume of 12,400 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the shares of the company are sold short.

Dominari Stock Up 4.8 %

Shares of DOMH stock opened at $2.18 on Tuesday. The stock has a 50-day simple moving average of $2.18 and a 200 day simple moving average of $2.24. Dominari has a fifty-two week low of $1.76 and a fifty-two week high of $3.76.

Insider Activity

In other Dominari news, CEO Anthony Hayes purchased 70,000 shares of the stock in a transaction dated Wednesday, December 20th. The shares were bought at an average cost of $2.00 per share, with a total value of $140,000.00. Following the completion of the acquisition, the chief executive officer now owns 98,804 shares of the company’s stock, valued at $197,608. The purchase was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders have acquired 87,000 shares of company stock valued at $183,850. Company insiders own 9.74% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DOMH. Citadel Advisors LLC bought a new position in Dominari during the second quarter valued at about $52,000. State Street Corp acquired a new position in shares of Dominari in the 2nd quarter valued at $58,000. Renaissance Technologies LLC acquired a new position in shares of Dominari in the 2nd quarter valued at $109,000. Geode Capital Management LLC acquired a new position in shares of Dominari in the 2nd quarter valued at $126,000. Finally, BlackRock Inc. acquired a new position in shares of Dominari in the 2nd quarter valued at $219,000. Institutional investors own 11.90% of the company’s stock.

Dominari Company Profile

(Get Free Report)

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

Recommended Stories

Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.